Medtech Talk

Julie Allen, principal of Allen Partners, shares insights on how Medtech executives must work to find the right fit and how companies can build their best team.

The experienced CEOs on this panel have authored some of the greatest stories in Medtech. In this discussion, they delve into their approaches to managing start-ups to multi-million – or billion – dollar acquisitions or IPOs. How do they accurately assess a struggling company and direct a team to turn weakness into strength?

Medtronic executive VP Geoff Martha talks with OISTV about how the Medtech giant views robotics, payers, and where health care transformation is the most difficult. The podcast also includes a clip from his keynote interview at the Medtech Conference.

For years, Intuitive Surgical appeared to be the only company capable of cracking the code for medical robotics. But with companies like Medtronic, Stryker, Johnson & Johnson, Google, and others creating their own efforts the sector appears to be stabilizing. Is there room for early-stage entrepreneurs and VC investors in this capital-intensive sector?

After five years and $25 million, Vascular Solutions CEO Howard Root watched a jury confirm what he knew all along. His company had done nothing wrong. In this interview, Root and Mark Duval, who is advising companies in this area but didn’t work with Vascular Solutions, explain what all this means for Medtech executives.

Mark Leahey, CEO and President of MDMA, delivers his “State of the Industry” address on reimbursement, the medical device tax, UnitedHealthcare/Medtronic and a little bit of Presidential Politics.

A recent jury decision cleared Vascular Solutions of charges of improper off-label marketing. Former Acclarent CEO Bill Facteau discusses his indictment in a similar case, the coming court case, and the support he has received.

Abbott’s move to acquire St. Jude demonstrates how Medtronic’s moves toward “Total Solutions” may change the game in Medtech. We’re going to tackle that topic at the June 1 Medtech Conference. Our conference co-chairs discuss that piece of our upcoming agenda as well as our focus on robotics.

Though initially surprised by Medtronic’s move to buy Covidien, Stacy Enxing Seng says she immediately saw the wisdom of the deal and recognized the opportunity for a fresh start. In an interview, Enxing Seng explains why she left, what she’s been doing, and how her new role at Lightstone Ventures fits her vision for Medtech’s future.

Thomas Gunderson watched the Medtech market for over 20 years at Piper Jaffray. Now recently retired, Gunderson explains how innovation in Medtech is changing, what big strategics think, and where Google might fit into the picture.